Johnson & Johnson Reports TREMFYA QUASAR Maintenance Study In UC Met Its Primary Endpoint And All Major Secondary Endpoints, Including Highly Statistically Significant Rates Of Endoscopic Remission
Portfolio Pulse from Benzinga Newsdesk
Johnson & Johnson announced that its Phase 3 QUASAR Maintenance Study for TREMFYA in treating ulcerative colitis met its primary and all major secondary endpoints, showing significant rates of clinical and endoscopic remission.
May 20, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Johnson & Johnson's TREMFYA met its primary and all major secondary endpoints in the Phase 3 QUASAR Maintenance Study for ulcerative colitis, showing significant clinical and endoscopic remission rates.
The successful results from the Phase 3 QUASAR Maintenance Study for TREMFYA indicate a strong potential for the drug in treating ulcerative colitis, which could lead to increased sales and positive investor sentiment for Johnson & Johnson.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100